Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to
reduce platelet reactivity and to prevent thrombotic events in patients treated with …

P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the
secondary prevention of thrombotic events in vascular diseases. Within the past few years …

Background The relation between platelet reactivity and stent thrombosis, major bleeding,
and other adverse events after coronary artery implantation of drug-eluting stents has been …

Background Dual antiplatelet therapy (DAPT) cessation increases the risk of adverse events
after percutaneous coronary intervention (PCI). Whether risk changes over time, depends on …

Light transmission aggregometry (LTA), which was independently developed in 1962 by
Born 1 and O'Brien 2, is considered the gold standard for testing platelet function, because it …

Objectives: This study sought to evaluate whether prasugrel may serve as an alternative to
clopidogrel in patients with triple therapy. Background: Approximately 10% of patients who …

Background ADP-specific platelet function assays were shown to predict thrombotic events,
and might be helpful to select candidates for more potent antiplatelet therapy. We aimed to …

2786 Circulation December 24/31, 2013 platelet adhesiveness, persistently high platelet
counts, and decreased or impaired fibrinolysis. 20–22 Adding to the withdrawal of protection …

This review is a critical evaluation of publications in the past decade on the usefulness of
platelet function tests (PFTs) in clinical cardiology, in aiding diagnosis, predicting risk, and …

Recurrent atherothrombotic events in patients with acute coronary syndromes (ACS) and/or
those undergoing percutaneous coronary intervention (PCI) are essentially platelet‐driven …